Imiquimod

Drug Profile

Imiquimod

Alternative Names: Aldara; Beselna Cream 5%; DZ 2636; MTD-39; R 837; S 26308; Vyloma; Zyclara

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Maastricht University; Meda; Medicis Pharmaceutical Corporation; Mochida Pharmaceutical
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Genital warts; Herpes simplex virus infections
  • Phase III Cervical intraepithelial neoplasia
  • Phase II Warts
  • No development reported Molluscum contagiosum; Photodamage; Tinea pedis; Vulvar intraepithelial neoplasia
  • Discontinued Hepatitis B; Hepatitis C; HIV infections

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 20 Jun 2016 Maastricht University Medical Center terminates the phase III TOPIC trial in Cervical intraepithelial neoplasia in Netherlands (Topical) because of insufficient enrolment (NCT02329171)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top